Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Carfilzomib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Carfilzomib as a study intervention. Browse Carfilzomib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
193
Shown on this page
12
Current sort
Recently updated
Therapy scope
Carfilzomib
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Carfilzomib. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 13–24 of 193 matching trials for Carfilzomib.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 2 Interventional Results available

Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma

NCT01559935
View directory record Official record
Conditions
Multiple Myeloma
Interventions
carfilzomib, Dexamethasone, Clarithromycin, Lenalidomide
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 17, 2026, 1:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

NCT04973605
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Sonrotoclax, Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • Irvine, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 17, 2026, 1:14 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

NCT05050097
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Talquetamab, Carfilzomib, Daratumumab SC, Lenalidomide, Pomalidomide
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 17, 2026, 1:14 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Daratumumab

NCT05438043
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Carfilzomib, Dexamethasone, Lenalidomide, Pomalidomide
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
7
States / cities
Miami, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 1:14 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

NCT05552976
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
Mezigdomide, Carfilzomib, Dexamethasone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
33
States / cities
Mobile, Alabama • Cerritos, California • Irvine, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 17, 2026, 1:14 PM EDT
Recruiting Phase 2 Interventional

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

NCT05789303
View directory record Official record
Conditions
Multiple Myeloma, Relapse Multiple Myeloma
Interventions
Belantamab mafodotin, Carfilzomib, Pomalidomide, Dexamethasone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 17, 2026, 1:14 PM EDT
Recruiting Phase 2 Interventional

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

NCT04661137
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor 60 MG, Selinexor 80 MG, Selinexor 100 MG, Carfilzomib, Pomalidomide, Daratumumab, Dexamethasone
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 1:14 PM EDT
Recruiting Phase 1 Interventional

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

NCT03909412
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Cyclophosphamide, Dexamethasone, Granulocyte Colony-Stimulating Factor
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 1:14 PM EDT
Active, not recruiting Phase 2 Interventional

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

NCT04933539
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Carfilzomib, Daratumumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 17, 2026, 1:14 PM EDT
Active, not recruiting Phase 2 Interventional

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

NCT04883242
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Carfilzomib, Dexamethasone, Isatuximab, Pomalidomide, Bone Marrow Biopsy, Bone Marrow Aspiration, Skeletal Survey X-Ray, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging
Drug · Biological · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 17, 2026, 1:14 PM EDT
Active, not recruiting Phase 2 Interventional

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

NCT03004287
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Thalidomide, Dexamethasone, Daratumumab, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide, Melphalan, ASCT, Lenalidomide, Bortezomib
Drug · Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 17, 2026, 1:14 PM EDT
Recruiting Phase 3 Interventional

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

NCT06615479
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma (RRMM)
Interventions
BMS-986393, Cyclophosphamide, Fludarabine, Daratumumab, Pomalidomide, Dexamethasone, Carfilzomib
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 17, 2026, 1:14 PM EDT

About this Carfilzomib clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Carfilzomib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Carfilzomib.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Carfilzomib.